secwatch / observer
8-K filed September 17, 2021, 7:59 PM ET ticker PRLD CIK 0001678660
leadership confidence high sentiment neutral materiality 0.50

EVP and Chief of Business Operations Christopher Pierce resigns effective Sept 30, 2021

Prelude Therapeutics Inc

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Pierce

Executive Vice President and Chief of Business Operations
PRLD · Prelude Therapeutics Inc
Effective
2021-09-30
Filed
September 17, 2021, 7:59 PM ET
On September 16, 2021, Prelude Therapeutics Incorporated. (the “Company”) received notice from Christopher Pierce of his intention to resign as Executive Vice President and Chief of Business Operations of the Company effective on September 30, 2021, in order to pursue another employment opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher Pierce resigned as Executive Vice President and Chief of Business Operations at Prelude Therapeutics Inc.

Action
resigned
Role
Executive Vice President and Chief of Business Operations
Exact text from the filing
On September 16, 2021, Prelude Therapeutics Incorporated. (the “Company”) received notice from Christopher Pierce of his intention to resign as Executive Vice President and Chief of Business Operations of the Company effective on September 30, 2021, in order to pursue another employment opportunity.
View on SEC.gov

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR
accession 0001193125-21-275680
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.